Allopurinol hypersensitivity: investigating the cause and minimizing the risk. - Wikidata - awgldk - TriplyDB

Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

http://www.wikidata.org/entity/Q38594891

about

Review: Gout: A Roadmap to Approaches for Improving Global Outcomes Allopurinol: insights from studies of dose-response relationships.Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.Current and future therapies for gout.Treatment Options for Gout.Management of Gout and Hyperuricemia in CKD.The safety of treatment options available for gout.Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review.In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper.Lesinurad: what the nephrologist should know.Arctium minus crude extract presents antinociceptive effect in a mice acute gout attack model.The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.Diagnosing and managing patients with drug hypersensitivity.Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience.Treatment of gout: where are we now?Genetic Testing in Clinical Settings.Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al.Patterns of progression of chronic kidney disease at later stages.Physiology of Hyperuricemia and Urate-Lowering Treatments.

P2860

Q28076018-D2C24755-6C77-453A-9E95-B7ECF8886C79 Q30240163-1CA7929F-7FE0-460C-9DC0-DFB557A13145 Q38600529-563BC460-12DB-416C-AB0D-F123F5621A7F Q38660829-DC5C12D4-EEA1-4A2A-9CB9-2AE960DD4E90 Q38691902-703D055A-4F58-4BE5-B126-C2B268C0646E Q38812962-5D4C6260-A268-472A-9E24-33369694EF2C Q39092018-F1F059B0-8BA3-48AD-980D-CD1452990BBD Q39203629-E1B63331-6FCF-4FB0-9BB9-8BE35E9BC250 Q39909074-18576870-019C-448F-95C3-36D655698E22 Q42091820-45F85DA8-C505-4980-A911-50768CAA841A Q46322024-47D0B479-4DAE-4B40-8AE5-38E5D9D16B4D Q47099047-61F06B3F-FC28-4930-9F4C-61E1DF2FF0F2 Q47569828-C8961C1C-FD8E-4932-94E9-27159D3A3EB4 Q48275640-16AFBE77-1765-45D6-807E-233AF5334C7A Q49616087-F365DFB5-28A0-4C73-AFF9-D3A8EF4FE606 Q52588359-18E49EFD-52ED-40EA-8275-8446F6812BE9 Q54298991-D8F3DDBD-2261-4A42-ABEA-1757674FEA77 Q55000470-7DAF4AB2-C12B-4585-918A-39309E6647A8 Q55163806-6BF0C5CB-0BB4-4A5A-A364-3841D5CCBF93

P2860

Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

http://www.wikidata.org/entity/Q38594891

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

@en

type

label

Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

@en

prefLabel

Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

@en

P1433

Q38594891-ED9497FE-0D82-458D-9012-835A53B59266

P1476

Q38594891-AA9AE3CC-A31B-435A-BEDB-49C07857005E

P2093

Q38594891-1F334B30-1917-458A-8E7A-E341134ABDCE

Q38594891-62FEC26F-3361-4140-B1F1-361F23CB8BAE

P2860

Q38594891-04107791-986A-4242-A0BC-34F2C8A1CE20

Q38594891-04EE6F53-D83C-4B83-BD27-FCE955161A99

Q38594891-1CAE7D63-ECE2-4D15-8792-84758089D953

Q38594891-1DD696FD-8104-4956-9496-5374521A589B

Q38594891-2390BF29-FF86-4B81-ADA3-8DFE8C67D04D

Q38594891-2A753891-1D28-4145-9FEE-321951DE5734

Q38594891-32830AEC-6A9A-422C-AF43-39C18EDF90A8

Q38594891-34ED18B2-97CD-4F9A-B4EE-5AD5D202D38C

Q38594891-3B454406-037E-45BA-99C5-A5868700B6D8

Q38594891-4512FD68-D520-4F7D-A453-D037C0BE4FCF

P2888

Q38594891-05F08206-C930-40A2-B2F0-8BA8EB3B5584

P304

Q38594891-FF986212-59A8-4F7D-BD3F-F9231960EA91

P31

Q38594891-475968F5-AA88-4F87-B893-A8027ADEDB1D

P356

Q38594891-259BD358-9984-4612-988C-700C4D215192

P407

Q38594891-62B21B1F-E7AE-4499-8848-CB62E18FA8DF

P433

Q38594891-8BE48E9F-FE92-49A8-8DC1-4B7A7628813D

P478

Q38594891-C781942E-C76B-4B9C-8161-2C275766FE83

P50

Q38594891-0E78EF35-8171-43E1-86F0-A8E44DB26EB6

P577

Q38594891-6E1EFA09-D6E3-4251-8593-E45B3FF543AF

P6179

Q38594891-18A0DA4F-7351-4462-A038-8E066413E8C2

P698

Q38594891-DB1A7C5E-792B-4369-91A2-AED41AD7BE27

P356

NRRHEUM.2015.132

P1433

Nature Reviews Rheumatology

P1476

Allopurinol hypersensitivity: investigating the cause and minimizing the risk

@en

P2093

Lisa K Stamp

http://www.w3.org/2001/XMLSchema#string

Richard O Day

http://www.w3.org/2001/XMLSchema#string

P2860

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Relation between adverse events associated with allopurinol and renal function in patients with gout

Prediction of creatinine clearance from serum creatinine

Acute adverse reactions attributed to allopurinol in hospitalised patients

DRESS syndrome: Part II. Management and therapeutics.

P2888

nrrheum.2015.132

P304

235-242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRRHEUM.2015.132

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1019600971

http://www.w3.org/2001/XMLSchema#string

P698

26416594

http://www.w3.org/2001/XMLSchema#string